Journal article

Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging

Madeline H Meier, Idan Shalev, Terrie E Moffitt, Shitij Kapur, Richard SE Keefe, Tien Y Wong, Daniel W Belsky, Honalee Harrington, Sean Hogan, Renate Houts, Avshalom Caspi, Richie Poulton

AMERICAN JOURNAL OF PSYCHIATRY | AMER PSYCHIATRIC PUBLISHING, INC | Published : 2013

Abstract

OBJECTIVE: Retinal and cerebral microvessels are structurally and functionally homologous, but unlike cerebral microvessels, retinal microvessels can be noninvasively measured in vivo by retinal imaging. The authors tested the hypothesis that individuals with schizophrenia exhibit microvascular abnormality and evaluated the utility of retinal imaging as a tool for schizophrenia research. METHOD: Participants were members of the Dunedin Study, a population-representative cohort followed from birth with 95% retention. Study members underwent retinal imaging at age 38. The authors assessed retinal arteriolar and venular caliber for all members of the cohort, including individuals who developed ..

View full abstract

Grants

Awarded by National Institute on Aging


Awarded by U.K. Medical Research Council


Awarded by National Institute on Drug Abuse


Awarded by National Institute of Child Health and Human Development


Awarded by Medical Research Council


Awarded by EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT


Awarded by NATIONAL INSTITUTE ON AGING


Awarded by NATIONAL INSTITUTE ON DRUG ABUSE


Funding Acknowledgements

Dr. Kapur has received grant support from AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline and has served as a consultant, scientific adviser, or speaker for AstraZeneca, Bioline, Bristol-Myers Squibb, Eli Lilly, Janssen (Johnson & Johnson), Lundbeck, Neuro-Search, Otsuka, Pfizer, Roche, Servier, Solvay, and Wyeth. Dr. Keefe has received investigator-initiated research support from the Department of Veterans Affairs, Feinstein Institute for Medical Research, GlaxoSmithKline, NIMH, Novartis, Psychogenics, Research Foundation for Mental Hygiene, and the Singapore National Medical Research Council and has served as a speaker, consultant, or advisory board member for Abbott, Akebia, Amgen, Astellas, Asubio, BiolineRx, Biomarin, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, and Targacept; he also receives royalties from the BACS testing battery and the MATRICS Battery (BACS Symbol Coding) and is a shareholder in NeuroCog Trials. The other authors report no financial relationships with commercial interests.Supported by grant AG032282 from the National Institute on Aging and grant MR/K00381X from the U.K. Medical Research Council. The Dunedin Multidisciplinary Health and Development Research Unit is supported by the New Zealand Health Research Council. Dr. Meier was supported by grant P30 DA023026 from the National Institute on Drug Abuse. Dr. Shalev was supported by grant HD061298 from the National Institute of Child Health and Human Development and the Jacobs Foundation. Dr. Belsky was supported by grant T32AG000029 from the National Institute on Aging.